On Tuesday, Aditxt Inc. (ADTX) announced that its wholly owned subsidiary, Ignite Proteomics, signed a definitive business combination agreement that values the precision oncology company at approximately $150 million. The deal is designed to separate Ignite from Aditxt and turn it into an independent public company through a newly formed holding company, expected to be named Ignite Proteomics Inc. Aditxt itself is expected to remain a separate Nasdaq-listed company, subject to continued compliance with listing requirements.

After the deal closes, Ignite and the acquisition corporation will become wholly owned subsidiaries of the new holding company. Ignite's common stock and public warrants are expected to trade on the New York Stock Exchange, pending regulatory approvals and customary closing conditions.

Ignite develops a functional proteomics platform that directly measures protein and phosphoprotein activity in tumor tissue to support precision oncology treatment decisions. Right now, the company focuses on breast cancer, but it plans to expand into additional tumor types.

Aditxt said the transaction is intended to unlock the value of its 100%-owned subsidiary while giving Ignite more visibility and access to growth capital. The proceeds are expected to fund commercialization efforts, clinical evidence generation, and general corporate purposes. The deal still needs shareholder, regulatory, and listing approvals.

Stock Performance And Technical Analysis

Aditxt shares are trading lower by about 28% during Wednesday's premarket session as risk appetite stays weak for high-volatility microcaps. Nasdaq futures are down 1.57%, while S&P 500 futures have shed 1.06%.

The chart is still in a steep long-term downtrend, and the stock is trading far below its major moving averages—about 97.4% below the 20-day SMA (78 cents) and about 99.7% below the 50-day SMA ($6.63). That kind of separation usually signals that rallies get sold into quickly, because prior breakdown areas overhead act like supply.

Momentum is extremely stretched: the RSI is 11.78, which measures how "overdone" the recent selling is. Readings this low typically fall into oversold territory. Oversold doesn't guarantee a bounce, but it does raise the odds of sharp snapback attempts—especially if sellers pause and liquidity returns after the open.

From a trend-structure standpoint, the moving-average stack remains bearish, with the 20-day SMA below the 50-day SMA and the 50-day SMA below the 200-day SMA. The stock also sits below its 52-week low of 3 cents, which keeps the technical backdrop fragile because there's little visible chart support from the past year.

Price Action

ADTX Stock Price Activity: Aditxt shares were down 28.55% at $0.02 during premarket trading on Wednesday.